Abstract
Osteoarthritis (OA) is the most common among all musculoskeletal disorders, becoming the main cause of chronic pain, impaired static and dynamic function and disability among the elderly, and represents the main burden for public health worldwide. Modern pharmacological treatment methods of OA are focused on reducing the disease symptoms and the pain syndrome intensity. One method in this direction is the use of symptom-modifying slow-acting drugs, which have shown promising positive effects on pain and other OA symptoms. The article presents an overview of the main experimental and clinical studies, and meta-analyses devoted to the evaluation of chondroitin sulfate (CS) efficacy and safety as one of the most commonly prescribed drugs for the treatment of OA. Some studies are devoted to the assessment of structural changes in articular cartilage during CS and placebo therapy, while others focus on the dynamics of pain syndrome and the degree of functional insufficiency, and on the assessment of the incidence and time of delayed knee replacement. The place of CS in the structure of EULAR and ESCEO recommendations is considered. KEYWORDS: osteoarthritis, chondroitin sulfate, symptom-modifying slow-acting drugs, medial condyle, articular cartilage thickness, articular replacement. FOR CITATION: Alabut A.V. Chondroitin sulfate: treatment tactics in osteoarthritis. Russian Medical Inquiry. 2021;5(2):102–106. DOI: 10.32364/2587-6821-2021-5-2-102-106.
Highlights
Osteoarthritis (OA) is the most common among all musculoskeletal disorders, becoming the main cause of chronic pain, impaired static and dynamic function and disability among the elderly, and represents the main burden for public health worldwide
Modern pharmacological treatment methods of OA are focused on reducing the disease symptoms
One method in this direction is the use of symptom-modifying slow-acting drugs
Summary
Osteoarthritis (OA) is the most common among all musculoskeletal disorders, becoming the main cause of chronic pain, impaired static and dynamic function and disability among the elderly, and represents the main burden for public health worldwide. Получавшие ХС, показали значи тельно меньшую потерю объема хряща, чем пациенты груп пы плацебо, уже через 6 мес. Для всего коленного сустава (p=0,030), латерального компартмента (p=0,015) и больше берцового плато (p=0,002), при этом значительная разница сохранялась через 12 мес.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
